184 related articles for article (PubMed ID: 31673656)
21. Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques.
Morgan TM; Press RH; Cutrell PK; Zhang C; Chen Z; Rahnema S; Sanda M; Pattaras J; Patel PR; Jani AB; Rossi PJ
J Contemp Brachytherapy; 2018 Dec; 10(6):495-502. PubMed ID: 30662471
[TBL] [Abstract][Full Text] [Related]
22. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
23. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15).
Aghdam N; Pepin A; Buchberger D; Hirshberg J; Lei S; Ayoob M; Danner M; Yung T; Kumar D; Collins BT; Lynch J; Kataria S; Suy S; Collins SP
Front Oncol; 2020; 10():1060. PubMed ID: 32719744
[No Abstract] [Full Text] [Related]
25. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
26. Urinary symptom flare following I-125 prostate brachytherapy.
Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
[TBL] [Abstract][Full Text] [Related]
27. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
[TBL] [Abstract][Full Text] [Related]
28. Cost minimization analysis of various treatment options for surgical stage I endometrial carcinoma.
Konski AA; Bracy PM; Jurs SG; Weiss SJ; Zeidner SR
Int J Radiat Oncol Biol Phys; 1997 Jan; 37(2):367-73. PubMed ID: 9069309
[TBL] [Abstract][Full Text] [Related]
29. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
30. Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone? : A prospective, randomized, controlled trial.
Yan M; Xue P; Wang K; Gao G; Zhang W; Sun F
Strahlenther Onkol; 2017 Sep; 193(9):714-721. PubMed ID: 28612083
[TBL] [Abstract][Full Text] [Related]
31. Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer: Results From a Prospective Trial.
Kollmeier MA; McBride S; Varghese M; Debonis D; Zhang Z; Cohen G; Damato AL; Mychalczak B; Gewanter R; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):905-913. PubMed ID: 32505609
[TBL] [Abstract][Full Text] [Related]
32. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
[TBL] [Abstract][Full Text] [Related]
33. Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life.
Harris AA; Wu M; Deirmenjian JM; Shea SM; Kang H; Patel R; Fielder D; Mysz ML; Harkenrider MM; Solanki AA
Brachytherapy; 2021; 20(1):66-74. PubMed ID: 33160849
[TBL] [Abstract][Full Text] [Related]
34. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer.
Lee WR; McQuellon RP; Harris-Henderson K; Case LD; McCullough DL
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):77-81. PubMed ID: 10656376
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.
Shaikh T; Li T; Handorf EA; Johnson ME; Wang LS; Hallman MA; Greenberg RE; Price RA; Uzzo RG; Ma C; Chen D; Geynisman DM; Pollack A; Horwitz EM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):722-731. PubMed ID: 28244407
[TBL] [Abstract][Full Text] [Related]
36. Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score.
Sakayori M; Ohashi T; Momma T; Kaneda T; Nishimura S; Sutani S; Yamashita S; Shigematsu N
Brachytherapy; 2017; 16(4):806-814. PubMed ID: 28552494
[TBL] [Abstract][Full Text] [Related]
37. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
38. Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor.
Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Nakai Y; Fujii T; Hasegawa M; Fujimoto K
Brachytherapy; 2018; 17(3):537-543. PubMed ID: 29402711
[TBL] [Abstract][Full Text] [Related]
39. Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy.
Kucera H; Mock U; Knocke TH; Kucera E; Pötter R
Acta Obstet Gynecol Scand; 2001 Apr; 80(4):355-60. PubMed ID: 11264612
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study.
Blanchard P; Pugh TJ; Swanson DA; Mahmood U; Chen HC; Wang X; Graber WJ; Kudchadker RJ; Bruno T; Feeley T; Frank SJ
Brachytherapy; 2018; 17(2):265-276. PubMed ID: 29269207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
